Want to see NAMS full AI Analyst Report?
Top Page
NewAmsterdam Pharma Company
(NASDAQ:NAMS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$20.00
▼(-25.35% Downside)
Action:Reiterated
Date:09/29/26
Overall score reflects weak fundamentals (large losses and sustained cash burn) and bearish technicals as the main drags, partially offset by a strong low-debt balance sheet and materially positive corporate developments highlighted by EU approval/commercialization progress for obicetrapib.
Positive Factors
EU Regulatory Approval
EU marketing authorization materially de-risks obicetrapib and moves the company from clinical development toward commercialization. The approval also creates potential milestone and tiered royalty income through Menarini, strengthening the lead asset’s strategic and financial value.
Negative Factors
Large Ongoing Losses
The company’s very large net loss shows that its current cost base is not supported by revenue, leaving profitability dependent on successful commercialization or future financing. Sustained losses can constrain strategic flexibility and increase the importance of execution across development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
EU Regulatory Approval
EU marketing authorization materially de-risks obicetrapib and moves the company from clinical development toward commercialization. The approval also creates potential milestone and tiered royalty income through Menarini, strengthening the lead asset’s strategic and financial value.
Read all positive factors
NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.36B
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth-88.87%
EPS Growth-35.06%
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding119,537,170
10 Day Avg. Volume1,284,320
30 Day Avg. Volume1,619,149
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue497.95
Enterprise Value/Gross Profit540.37
Enterprise Value/Ebitda-13.91
Forecast
1Y Price Target
$53.00Price Target Upside97.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$30.26M
NewAmsterdam Pharma Company Business Overview & Revenue Model
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CE...
NewAmsterdam Pharma Company Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.12M | 22.50M | 45.56M | 14.09M | 102.69M | 0.00 |
| Gross Profit | 6.56M | 22.44M | 45.56M | 14.09M | 102.69M | 0.00 |
| EBITDA | -254.91M | -242.32M | -241.49M | -176.86M | -22.34M | -41.37M |
| Net Income | -259.50M | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
Balance Sheet | ||||||
| Total Assets | 704.45M | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M |
| Cash, Cash Equivalents and Short-Term Investments | 633.85M | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M |
| Total Debt | 82.00K | 202.00K | 448.00K | 60.00K | 126.00K | 186.51K |
| Total Liabilities | 73.03M | 85.85M | 107.12M | 58.70M | 48.43M | 11.36M |
| Stockholders Equity | 631.42M | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M |
Cash Flow | ||||||
| Free Cash Flow | -143.72M | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
| Operating Cash Flow | -143.46M | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Investing Cash Flow | -34.91M | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 41.68M | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
NewAmsterdam Pharma Company Technical Analysis
Negative
26.79
Price Trends
23.57
Negative
27.29
Negative
30.13
Negative
Market Momentum
-0.87
Negative
35.75
Neutral
54.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 26.79 is above the 20-day moving average (MA) of 21.79, above the 50-day MA of 23.57, and below the 200-day MA of 30.13, indicating a bearish trend. The MACD of -0.87 indicates Negative momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 54.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.
NewAmsterdam Pharma Company Risk Analysis
NewAmsterdam Pharma Company disclosed 92 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewAmsterdam Pharma Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $2.86B | -11.29 | -37.17% | ― | ― | -47.00% | |
58 Neutral | $3.10B | -5.24 | -94.56% | ― | ― | -203.77% | |
53 Neutral | $2.36B | -9.04 | -38.33% | ― | -88.87% | -35.06% | |
52 Neutral | $1.51B | -6.99 | -16.91% | ― | ― | 1.47% | |
52 Neutral | $2.34B | -20.21 | -26.01% | ― | ― | -4.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NAMS
NewAmsterdam Pharma Company
19.71
-16.33
-45.31%
VKTX
Viking Therapeutics
24.40
-11.53
-32.09%
IRON
Disc Medicine
74.51
-15.14
-16.89%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
21.19
-7.46
-26.04%
MBX
MBX Biosciences, Inc.
48.50
31.06
178.10%
KLRA
Kailera Therapeutics, Inc.
12.85
-13.15
-50.58%
NewAmsterdam Pharma Company Corporate Events
Business Operations and StrategyProduct-Related Announcements
NewAmsterdam Pharma Begins Phase 2b Preclinical Alzheimer’s Trial
Positive
Sep 29, 2026
On September 29, 2026, NewAmsterdam Pharma reported dosing the first participant in SPINOZA, its Phase 2b randomized, double-blind, placebo-controlled trial evaluating obicetrapib in approximately 400 adults with preclinical Alzheimer’s dise...
Business Operations and StrategyProduct-Related Announcements
EU Approval of Obicetrapib Products Strengthens NewAmsterdam
Positive
Sep 21, 2026
On September 21, 2026, NewAmsterdam Pharma and its partner Menarini announced that the European Commission granted marketing authorization across the EU, Iceland, Liechtenstein and Norway for Ubeslo, an obicetrapib 10 mg monotherapy, and Evlarco, ...
Business Operations and StrategyExecutive/Board Changes
NewAmsterdam Pharma Appoints New Principal Accounting Officer
Positive
Aug 14, 2026
On August 10, 2026, NewAmsterdam Pharma Company N.V. appointed Robert W. Gunning as principal accounting officer and Vice President, Controller, succeeding Louise Kooij, whose departure effective August 31, 2026, had been previously announced. Gun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.